
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing spironolactone, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing spironolactone are listed in tablet and suspension forms. No finished spironolactone product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Spironolactone is a potassium-sparing diuretic and androgen-receptor blocker, commonly compounded into topical gels and creams and oral suspensions and capsules.
Spironolactone is a mineralocorticoid receptor antagonist. It blocks aldosterone in the kidney's distal tubule and collecting duct, so the body sheds sodium and water while holding on to potassium. It also binds androgen and progesterone receptors, which is why it can reduce sebum production and has antiandrogen effects. Manufactured Aldactone tablets (spironolactone) and generics are FDA-approved for heart failure with reduced ejection fraction, add-on treatment of hypertension, edema from cirrhosis or nephrotic syndrome, and primary hyperaldosteronism. Prescribers order spironolactone compounded when they want a topical form, which no manufacturer makes, a low or fractional oral strength, a liquid for patients who cannot swallow tablets, or a combination with another topical active. Compounded preparations are not FDA-approved and require a prescription.
The current Aldactone label carries no boxed warning. Its main warning is high blood potassium, which can be dangerous; potassium is checked within a week of starting or changing the dose and regularly after. Risk rises with kidney impairment and with ACE inhibitors, ARBs, NSAIDs, heparin, trimethoprim, potassium supplements or potassium salt substitutes. Spironolactone is contraindicated in hyperkalemia, Addison's disease and with eplerenone. It can lower blood pressure and worsen kidney function with excessive fluid loss, raise lithium levels, and cause breast enlargement or tenderness in men, which is dose related and usually reversible. Rare serious skin reactions and liver injury have been reported. Pregnancy: animal data suggest antiandrogen effects could feminize a male fetus; the label advises avoiding use or discussing that risk. Breastfeeding: the metabolite canrenone appears in milk at low levels, with no adverse effects in reported infants. Talk to your prescriber or pharmacist about muscle weakness, irregular heartbeat, confusion or decreased urination.
Spironolactone competitively antagonizes aldosterone at the mineralocorticoid receptor and has antiandrogen activity through androgen-receptor binding and inhibition of sebocyte proliferation. Oral absorption is enhanced by food (AUC roughly doubled), so meal timing should be consistent; spironolactone and its metabolites are over 90 percent protein bound. Parent half-life is about 1.4 hours; the active metabolites canrenone, TMS and HTMS have half-lives of about 16.5, 13.8 and 15 hours, which govern duration of effect. Metabolites are excreted mainly in urine with secondary biliary elimination, and clearance falls in cirrhosis. Labeled indications (Aldactone): HFrEF, hypertension, edematous states of cirrhosis and nephrotic syndrome, and primary hyperaldosteronism. StatPearls lists off-label oral use in adult female acne and hirsutism. Prescribers have ordered compounded topical spironolactone gels, including combinations with niacinamide and tretinoin, as listed in DailyMed for outsourcing-facility products. Dosing is per prescriber. Monitor potassium and renal function at baseline, within a week of initiation or titration and periodically; sodium, magnesium and glucose in long-term use; note that spironolactone metabolites interfere with digoxin radioimmunoassays. Not a controlled substance.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth